Brief: Salarius Provides Update On Strategic Review Process

Decoy Therapeutics

22/02/2024 14:47

Feb 22 (Reuters) - Salarius Pharmaceuticals Inc
 SLRX.O :
    * SALARIUS PROVIDES UPDATE ON STRATEGIC REVIEW PROCESS AND
PLANS
TO SUPPORT ONGOING SECLIDEMSTAT CLINICAL TRIALS BY FURTHER
REDUCING EXPENSES
    * SALARIUS PHARMACEUTICALS INC: IMPLEMENTING A SERIES OF
COST-SAVINGS MEASURES DESIGNED TO EXTEND SALARIUS' EXPECTED CASH
RUNWAY INTO FIRST HALF OF 2025
    * SALARIUS PHARMACEUTICALS: PRESIDENT AND CEO, HAS ENDED HIS
FULL-TIME EMPLOYMENT AND TRANSITIONED TO A PART-TIME CONSULTANT
ROLE
    * SALARIUS PHARMACEUTICALS INC: DAVID ARTHUR, PRESIDENT &
CEO TO
CONTINUE TO SERVE AS CEO AND SUPPORT SALARIUS' ONGOING
ACTIVITIES
    * SALARIUS PHARMACEUTICALS: COST-SAVINGS INCLUDE REDUCING
OPERATING EXPENSES, CASH COMPENSATION PAYABLE TO NON-EMPLOYEE
DIRECTORS BEGINNING IN Q2 2024

Source text for Eikon:  ID:nGNX6vbcmK 
Further company coverage:  SLRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))